Indivior (INDV) Stock Price, News & Analysis

Company Overview

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine. The company is headquartered in Slough, United Kingdom, with a major operations and manufacturing hub in Richmond, Virginia. Since its inception, Indivior has sought to expand access to evidence-based treatments through ongoing clinical research and strategic collaborations.

Beyond its core opioid dependence offerings, Indivior maintains a pipeline of investigational therapies aimed at addressing alcohol use disorder and other psychiatric conditions. The company invests in clinical development programs to explore novel formulations, delivery technologies and digital health solutions intended to enhance treatment adherence and patient outcomes.

Today, Indivior markets its products across North America, Europe, Australia and other key regions, supporting healthcare professionals with educational and patient-support initiatives. Through its global footprint, the company aims to reduce barriers to care and improve long-term recovery rates for individuals affected by addiction worldwide.

Key Stats

• Today's Range: $34.55 to $35.31
• 50-Day Range: $34.56 to $41.30
• 52-Week Range: $22.22 to $42.81
• Volume: 1.02 million shs
• Average Volume: 2.04 million shs
• Market Capitalization: $4.12 billion
• P/E Ratio: 12.52
• Dividend Yield: N/A
• Price Target: $45.17
• Consensus Rating: Moderate Buy

Indivior Stock Analysis - MarketRank™

Indivior scored higher than 82% of companies evaluated by MarketBeat, and ranked 102nd out of 911 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Indivior has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 5 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

Indivior has a consensus price target of $45.17, representing about 29.3% upside from its current price of $34.94.

Amount of Analyst Coverage

Indivior has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 4.64%

Earnings Growth

Earnings for Indivior are expected to grow by 4.64% in the coming year, from $3.66 to $3.83 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Indivior is 12.52, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 42.60.

Price to Earnings Ratio vs. Sector

The P/E ratio of Indivior is 12.52, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 213.35.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.92% of the float of Indivior has been sold short.

Short Interest Ratio / Days to Cover

Indivior has a short interest ratio ("days to cover") of 3.27, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Indivior has recently decreased by 3.96%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Indivior does not currently pay a dividend.

Dividend Growth

Indivior does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.82

News Sentiment

Indivior has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Indivior this week, compared to 3 articles on an average week.

Search Interest

Only 3 people have searched for INDV on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added Indivior to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 2.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Indivior insiders have sold 1,865.47% more of their company's stock than they have bought. Specifically, they have bought $107,955.00 in company stock and sold $2,121,828.00 in company stock.

Percentage Held by Insiders

0.74% of the stock of Indivior is held by insiders.

Percentage Held by Institutions

60.33% of the stock of Indivior is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 6/30/2026
• Today: 9/05/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:INDV
• CIK: 1625297
• Web: www.indivior.com
• Phone: 804-379-1090
• Fax: 804-379-1215
• Employees: 1,051
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Indivior: $45.17
• High Price Target: $53.00
• Low Price Target: $36.00
• Potential Upside/Downside: +29.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.79
• Trailing P/E Ratio: 9.57
• Forward P/E Ratio: 9.55
• P/E Growth: N/A
• Net Income: $210 million
• Net Margins: 26.65%
• Pretax Margin: 29.50%
• Return on Equity: -283.11%
• Return on Assets: 36.85%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.84
• Quick Ratio: 0.66

Sales & Book Value

• Annual Sales: $1.24 billion
• Price / Sales: 3.33
• Cash Flow: $2.72 per share
• Price / Cash Flow: 12.85
• Book Value: ($1.76) per share
• Price / Book: -19.85

Miscellaneous

• Outstanding Shares: 118,010,000
• Free Float: 117,141,000
• Market Cap: $4.12 billion
• Optionable: Not Optionable
• Beta: 0.82